Hagens Berman, an investor-rights law firm, today announced that it is investigating Abiomed, Inc. (NASDAQ:ABMD) (“Abiomed”) for potential violations of the securities laws following the disclosure of a Department of Justice probe into the marketing and labeling of its flagship product, the Impella 2.5 system.